Benfotiamine in Patients With Early Alzheimer’s Disease

What is the Purpose of this Study?

The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called benfotiamine as a possible treatment for Alzheimer’s disease (AD). Benfotiamine is a lab-made version of vitamin B1 (thiamine). The study aims to determine whether the drug slows down the progression of the symptoms of early Alzheimer’s disease. Participants will be randomly assigned to receive either the study drug or placebo (inactive substance).


Eligibility

Not Available


Where can I participate?

Beverly


What is the full name of this clinical trial?

A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer?s Disease

Study Details
Disease Type/Condition

Other

Principal Investigator

Kremen, Sarah

Age Group

Adult

Phase

II

IRB Number

STUDY00002977


How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Other

Principal Investigator

Kremen, Sarah

Age Group

Adult

Phase

II

IRB Number

ADC-061-BENFO


Contact
Email
clinicaltrials@cshs.org